Complex approach to pelvic inflammatory diseases treatment

• Igor I. Baranov
• Kukarskaya I.I.
• Lyudmila Yu. Karakhalis
• Sukhanov A.A.
• Vinitsky A.A.

Abstract

The aim of the study was to compare clinical outcomes of complex therapy in patients with pelvic inflammatory diseases (PID) on the back of Longidaza ® administration with clinical outcomes of therapy without it.

Material and methods. The non-interventional unblinded two-arm study was conducted in 2 clinical centers. The study involved 240 patients at the ages from 18 to 45 years with proven diagnosis of acute or chronic (in the acute phase) PID (pelvic inflammatory disease). For women in the group 1 (n=170), Longidaza® 3000 IU was prescribed in form of suppositories as a part of complex therapy once every 3 days with a total rate of 20 administrations. Patients from the group 2 (n=70) took baseline therapy. The diagnostic stage included mandatory standard clinical and laboratory studies. Monitoring of patients from the moment of study entry lasted 60 days with intermediate evaluation stages on the 6th, 12^th and 30^th days.

Results. Lower abdominal pain syndrome in the group 1 was stopped much faster and in a larger number of patients. After 2 months of treatment 11 (6.5%) women, who took Longidaza® as a part of complex therapy, continued to complain of pain. In the group 2 same pictured was observed for 56 (80%) women (p<0.001). Pain attenuation in palpation and cervix traction in patients from the 1st group was absolute in all cases, while in the 2nd group this symptom was continued to be detected in 25.7% of women (p<0.001). Percent of patients with an increased uterine size after the therapy decreased by 56% in the group 1, and only by 15.7% (p<0.001) in the group 2. For 2 months of follow-up in the group 1 number of patients with normal WBC count in vaginal smear increased by more than 3.5 times, while in the group 2 - only 1.1 times from the reference values. At the end of follow-up 169 (99.4%) patients were indicated in group 1, and 59 (84.3%) patients were indicated in group 2.

Conclusion. Longidaza® administration as part of complex therapy of PID increases treatment effectiveness and also contributes to significantly earlier improvement in clinical status of patients, which determines its administration from the beginning of the treatment course.

Keywords:pelvic inflammatory diseases, Longidaza®, therapy, women

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)